World Astatine Community expands access to cancer-fighting At-211

June 20, 2023, 12:00PMNuclear News
Representatives from the U.S., EU, and Japan announce the WAC at the 12th International Symposium for Targeted Alpha Therapy. (Photo: NIDC)

The World Astatine Community (WAC) was formed earlier this year during the 12th International Symposium for Targeted Alpha Therapy by representatives from the United States, Japan, and the European Union to share astatine production technology and advance science and health care. The National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program (DOE-IP), announced the news on June 15 and explained how the United States plans to help expand the global supply of astatine-211.

Astatine-211 targets blood-borne cancers in Seattle clinical trials

September 13, 2022, 9:30AMNuclear News
A clinical dose of At-211 is prepared at the University of Washington for use in a Fred Hutchison Cancer Center clinical trial. (Photo: UW/Don Hamlin)

Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

Researchers report fastest purification of astatine-211 needed for targeted cancer therapy

February 24, 2021, 3:00PMANS Nuclear CafeVandana Suresh

Astatine-211 recovery from bismuth metal using a chromatography system. Unlike bismuth, astatine-211 forms chemical bonds with ketones.

In a recent study, Texas A&M University researchers have described a new process to purify astatine-211, a promising radioactive isotope for targeted cancer treatment. Unlike other elaborate purification methods, their technique can extract astatine-211 from bismuth in minutes rather than hours, which can greatly reduce the time between production and delivery to the patient.

“Astatine-211 is currently under evaluation as a cancer therapeutic in clinical trials. But the problem is that the supply chain for this element is very limited because only a few places worldwide can make it,” said Jonathan Burns, research scientist in the Texas A&M Engineering Experiment Station’s Nuclear Engineering and Science Center. “Texas A&M University is one of a handful of places in the world that can make astatine-211, and we have delineated a rapid astatine-211 separation process that increases the usable quantity of this isotope for research and therapeutic purposes.”

The researchers added that this separation method will bring Texas A&M one step closer to being able to provide astatine-211 for distribution through the Department of Energy’s Isotope Program’s National Isotope Development Center as part of the University Isotope Network.

Details on the chemical reaction to purify astatine-211 are in the journal Separation and Purification Technology.